Search results
Results From The WOW.Com Content Network
If a person without a Kidd blood antigen (for example a Jka-Jkb+ patient) receives a Kidd antigen (Jka-antigen for example) in a red blood cell transfusion and forms an alloantibody (anti-Jka); upon subsequent transfusion with Jka-antigen positive red blood cells, the patient may have a delayed hemolytic transfusion reaction as their anti-Jka antibody hemolyzes the transfused Jka-antigen ...
Transfusion hemosiderosis; Transfusion-associated circulatory overload; Transfusion-associated graft-versus-host disease; Transfusion-dependent anemia; Transfusion-related acute lung injury; Transfusion-related immunomodulation
It can occur due to a rapid transfusion of a large volume of blood but can also occur during a single red blood cell transfusion (about 15% of cases). [2] It is often confused with transfusion-related acute lung injury (TRALI), another transfusion reaction.
An acute hemolytic transfusion reaction (AHTR), also called immediate hemolytic transfusion reaction, is a life-threatening reaction to receiving a blood transfusion. AHTRs occur within 24 hours of the transfusion and can be triggered by a few milliliters of blood. The reaction is triggered by host antibodies destroying donor red blood cells.
Type IV hypersensitivity, in the Gell and Coombs classification of allergic reactions, often called delayed-type hypersensitivity, is a type of hypersensitivity reaction that can take a day or more to develop. [1] Unlike the other types, it is not humoral (not antibody-mediated) but rather is a type of cell-mediated response.
Serum sickness is a type III hypersensitivity reaction, caused by immune complexes. [2] When an antiserum is given, the human immune system can mistake the proteins present for harmful antigens . The body produces antibodies, which combine with these proteins to form immune complexes. [ 2 ]
Kidd antibodies are dangerous as they are capable of causing severe acute hemolytic transfusion reactions. They are unique in that they are capable of dropping to low or even undetectable levels after several months following an exposure. [5] Thus, on pre-transfusion testing, an anti-Jka or -Jkb may go undetected.
Temporary depletion of the T-cell population at the time of the transplant also risks delayed acute rejection, which may be missed and cause severe damage to the graft. Anti-IL-2Rα receptor antibodies such as basiliximab and daclizumab are increasingly being used in place of ATG as an induction therapy, as they do not cause cytokine release ...